Combs Andrew 4

What Happened

• Andrew Combs, Chief Chemistry Officer of Prelude Therapeutics (PRLD), received a 230,000-share derivative award (reported as acquisition code A) on Feb 4, 2026. The Form 4 lists the per-share acquisition amount as $0.00 and the reported cash value of the transaction as $0 (derivative award rather than an open-market purchase).

Key Details

• Transaction date: 2026-02-04; Form 4 filed 2026-02-05 (timely filing).
• Security: 230,000 shares reported as a derivative award (transaction code A).
• Reported acquisition price on Form 4: $0.00 (derivative award entry).
• Shares owned after transaction: not specified in the Form 4 filing.
• Footnote (F1): "The stock option vests as to 25% of the total shares on Feb 4, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."
• No 10b5-1 plan, tax withholding, or late-filing indication noted in the filing.

Context

• This was an equity award (derivative grant), not an immediate market purchase or sale. Such grants are typically used for compensation and retention; the shares/options only become exercisable/owned as they vest per the schedule above. The Form 4 lists $0 for the acquisition value because it reports the grant of derivative securities rather than a cash trade.